27 min listen
Programming Cell Therapies to Overcome Solid Tumor Defense Systems
FromThe Bio Report
ratings:
Length:
28 minutes
Released:
Sep 16, 2021
Format:
Podcast episode
Description
While CAR-T cell therapies have emerged as promising anti-cancer agents, their success have been focused on hematologic cancers. ArsenalBio is working to develop more robust cell therapies capable to treating a broader range of cancers by using synthetic biology to make them programable. We spoke to Ken Drazen, CEO of ArsenalBio, about the company’s next-generation T cell therapies, how it is able to program functions into these cells to overcome solid tumor defenses, and the company’s collaboration with Bristol-Myers Squibb announced at the start of the year.
Released:
Sep 16, 2021
Format:
Podcast episode
Titles in the series (100)
Remembering Industry Pioneer Ron Cape by The Bio Report